The clinical potential of antiangiogenic fragments of extracellular matrix proteins

Abstract

Neovasculature development is a crucial step in the natural history of a cancer. While much emphasis has been placed on proangiogenic growth factors such as VEGF, it is clear that endogenous angiogenesis inhibitors also have critical roles in the regulation of this process. Recent research has identified several cryptic fragments of extracellular matrix/vascular basement membrane proteins that have potent antiangiogenic properties in vivo. It has become apparent that many of these fragments signal via interactions with endothelial integrins, although multiple downstream effector pathways have been implicated and endostatin, the first non-collagenous domain of collagen XVIII, influences an intricate signalling network. The activity of these molecules in animal models suggests that they may have significant clinical activity; however, results of phase I/II trials with endostatin were disappointing. Many possible reasons can be found for the failure of these studies. Weaknesses in trial design, endostatin administration regimen and patient selection are identifiable, and importantly the lack of a clearly defined antiangiogenic mechanism for endostatin hindered assessment of biologically effective dose. Additionally, in vivo immunological and proteolytic function-neutralising mechanisms may have negated endostatin's actions. Lessons learned from these studies will aid the future clinical development of other antiangiogenic extracellular matrix protein fragments.

Human Kallikrein 8 Protease Confers a Favorable Clinical Outcome in Non–Small Cell Lung Cancer by Suppressing Tumor Cell Invasiveness

“…Recently, several ECM protein fragments with potent antiangiogenic properties have been isolated. These antiangiogenic properties were apparent only after proteolytic cleavage of their parental molecules (32). One study (33) showed that fragments of fibronectin were potent inhibitors of endothelial cell growth.…”

Molecularly targeted therapy for melanoma

“…41,42 These studies demonstrated that no clinically significant toxicities were associated with the administration of endostatin. 41 For example, among a group of 15 patients who received a total of 50 monthly cycles of daily 20-minute intravenous injections with doses ranging from 15 to 240 mg/m 2 per day experience only transient skin rashes at the highest doses.…”

A simple mechanistic model of sprout spacing in tumour-associated angiogenesis

“…We will discuss angiostatin and endostatin briefly here. For recent reviews of these and other antiangiogenic molecules, see Clamp and Jayson (2005), Folkman (2005), Ruegg et al (2006), Sim (1998).…”